TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07457294: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of 1% Clascoterone Cream in the Treatment of Acne Vulgaris

Sponsor: Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 692 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,723,520

Rescue Site Savings

+$7,730,196

Unlock Full NCT07457294 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07457294 Rescue Dossier →